Market Closed - Nasdaq 16:00:00 2024-05-13 EDT 5-day change 1st Jan Change
16.82 USD +1.02% Intraday chart for ZimVie Inc. +6.32% -5.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : ZimVie Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (ZIMV) ZIMVIE Reports Q1 EPS $0.08 MT
Earnings Flash (ZIMV) ZIMVIE Reports Q1 Revenue $118.2M, vs. Street Est of $116.4M MT
(ZIMV) ZIMVIE Expects Fiscal Year 2024 EPS Range $0.55 - $0.70 MT
ZimVie Inc. Provides Earnings Guidance for the Full Year 2024 Ending December 31, 2024 CI
ZimVie Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
H.I.G. Capital, LLC completed the acquisition of Zimmer Biomet Spine, Inc. from ZimVie Inc.. CI
ZimVie Inc.(NasdaqGS:ZIMV) added to S&P Healthcare Equipment Select Industry Index CI
Barclays Adjusts Price Target on ZimVie to $16 From $13, Maintains Underweight Rating MT
Transcript : ZimVie Inc., Q4 2023 Earnings Call, Feb 28, 2024
ZimVie Inc. Provides Earnings Guidance for First Quarter and Raises Earnings Guidance for the Full Year 2024 CI
ZimVie Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
(ZIMV) ZIMVIE Expects Q1 Revenue Range $115M - $118M MT
Earnings Flash (ZIMV) ZIMVIE Reports Q4 Revenue $113.1M MT
Earnings Flash (ZIMV) ZIMVIE Reports Q4 EPS $0.11, vs. Street Est of $0.13 MT
ZimVie Inc. Announces Launch of Next-Generation TSX®? Implant in Japan CI
Top Midday Gainers MT
ZimVie to Sell Spine Business to H.I.G. Capital for $375 Million; Shares Rise MT
H.I.G. Capital, LLC entered into an Equity Purchase Agreement to acquire Zimmer Biomet Spine, Inc. from ZimVie Inc. for approximately $380 million. CI
ZimVie Inc. Announces Compatibility Between Its Vital Spinal Fixation System and Brainlab Spine & Trauma Navigation CI
Needham Starts ZimVie With Hold Rating MT
Top Premarket Decliners MT
Transcript : ZimVie Inc., Q3 2023 Earnings Call, Nov 01, 2023
(ZIMV) ZIMVIE Forecasts Fiscal Year 2023 EPS Range $0.60 - $0.70 MT
Earnings Flash (ZIMV) ZIMVIE Reports Q3 Revenue $202.9M, vs. Street Est of $196M MT
Chart ZimVie Inc.
More charts
ZimVie Inc. is a global life sciences company in the dental market. The Company develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. The Company works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including dental implants, biomaterials, and digital workflow solutions. In the dental segment, its core services include designing, manufacturing and distributing dental implant systems. The key products in its dental implant systems portfolio include the T3 Implant, Tapered Screw-Vent Implant System, Trabecular Metal Dental Implant, BellaTek Encode Impression System, and Puros Allograft Particulate. The Company markets its products in about 70 countries in North America, Europe, Latin America and Asia.
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
16.82 USD
Average target price
16 USD
Spread / Average Target
-4.88%
Consensus
  1. Stock Market
  2. Equities
  3. ZIMV Stock
  4. News ZimVie Inc.
  5. Earnings Flash (ZIMV) ZIMVIE Reports Q4 Revenue $113.1M
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW